BPC-157 by prescription in the US

BPC-157 is a short chain of 15 amino acids, the building blocks of protein. It copies part of a protein first found in human stomach juice. All BPC-157 sold today is made in a lab.

You may also see it called Body Protection Compound 157, bepecin or PL-14736.

It is not FDA approved for any use. An FDA review in 2026 found no approved medicine that contains it in any country.

Online, it is promoted for gut problems and for healing tendons, muscles and joints. Most of that rests on animal studies, as the evidence section below explains.

Compounding is when a licensed pharmacy makes a drug for one patient on a prescription. Under federal law, a 503A pharmacy can usually only use ingredients that pass one of three tests. The ingredient is part of a drug the FDA has approved, has a USP monograph, or is on the FDA's 503A bulks list. BPC-157 passes none of them.

From September 2023 to April 22, 2026, the FDA kept BPC-157 on its Category 2 list. That list flags ingredients that may pose serious safety risks. BPC-157 came off it after the groups that nominated it withdrew. HHS says neither step changed its legal status.

In July 2026, the FDA's compounding advisory committee voted in favor of adding BPC-157 to the 503A bulks list. According to ABC News, the vote was 8 to 6, with one abstention. FDA staff had advised against it. The vote is advice only, and the FDA has not made a final decision.

On October 30, 2026, HHS published a notice in the Federal Register, FR Doc 2026-22192. HHS Secretary Robert F. Kennedy, Jr. signed it. The policy it announces lists six peptides, and BPC-157 is one of them.

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed doctor that compounds BPC-157 under the policy's conditions. This lasts until a final FDA rule decides whether BPC-157 goes on the 503A bulks list.

This is not FDA approval and it is not a final rule. The notice calls the policy a draft and takes public comments for two weeks. HHS says the policy is not binding and may be revisited if a safety or quality problem appears.

The pharmacy needs a valid prescription for you by name. It cannot sell BPC-157 to anyone without one.

For BPC-157, the policy covers injection under the skin or into a muscle, forms taken by mouth, and forms put on the skin. Nasal sprays are not on the list for BPC-157. The policy names the acetate salt form, called BPC-157 acetate.

Each product may contain only one active ingredient. Blends, such as BPC-157 mixed with TB-500, fall outside the policy. If a device comes in the pack, it must be an FDA-cleared syringe.

The raw peptide must come from a maker registered with the FDA. Each lot needs a certificate of analysis. It must show tests for identity, purity, strength and contaminants such as endotoxins and heavy metals.

For forms taken by mouth, the pharmacy must keep proof that the product is absorbed well enough in people. The FDA's July 2026 review found no human data on how BPC-157 is absorbed by mouth.

The label must say: "This is a compounded drug product. Not for resale." The pharmacy must report serious side effects and quality problems to the FDA through MedWatch.

Start with a visit, in person or by video, with a licensed prescriber. They should review your health history, your current medicines and why you want BPC-157. They decide whether a prescription is right for you.

The prescriber must be licensed in the state where you are at the time of the visit. HHS telehealth guidance says this. Ask which states they are licensed in before you book.

The prescription then goes to a state-licensed 503A compounding pharmacy. The pharmacy makes the product for you and ships it or has it ready to pick up. Not every pharmacy ships to every state, so ask before you pay.

In a proper prescription route, a prescriber approves you before you can check out for the peptide. A site that sells BPC-157 with no prescription, or as "research use only", is not using this route.

Most research on BPC-157 has been done in rats and in cells. Those studies suggest effects on healing in the gut, tendons and muscles. Animal results do not show that it works in people.

Human data is thin. The FDA's 2026 review found five small human studies. They gave BPC-157 as an enema, a knee joint injection, a bladder treatment or an IV drip. None tested shots under the skin, capsules or nasal sprays.

No serious side effects were reported in those studies. But they were small and short, and they gave few safety details.

A systematic review of its use for joints and healing, published in October 2026, found three human studies with 30 people in total. It rated the certainty of the evidence as very low.

A trial in healthy adults was registered in 2015 but never posted results. A placebo-controlled trial in hamstring strains began in 2026. A US trial after rotator cuff surgery is planned for 2027. Neither of the newer trials has results yet.

The FDA reviewed BPC-157 for ulcerative colitis. It found too little evidence to say whether it works for that condition.

The FDA says there is not enough clinical safety information to describe how safe BPC-157 is in people. The FDA found no studies of whether it raises cancer risk, and no full studies of effects on pregnancy.

A key FDA concern is immune reactions to injected or nasal peptides. Peptides can clump, and impurities from manufacturing can add risk. The FDA has side effect reports, such as injection site reactions and shortness of breath, but could not tell whether BPC-157 caused them.

Ask your prescriber: Which states are you licensed in? What is the evidence for my condition? What side effects should I watch for, and who do I contact if I have one? Is it safe with my other medicines, or if I am pregnant or have had cancer?

Ask the pharmacy: What is your name, and are you a 503A pharmacy licensed in my state? Who made the raw peptide, and is that maker registered with the FDA? Can I see the certificate of analysis for my lot, including endotoxin and sterility tests? Is BPC-157 the only active ingredient?

If you have a side effect, tell your prescriber. You can also report it to the FDA through MedWatch.

We checked 250 US sellers across the six peptides in the HHS policy. 164 ranked providers list BPC-157. What they charge: $75 to $445 a month, for the 10 of 21 that post a price and sell by the month. We leave out blend prices, and we never mix a monthly price with a price per vial. Check what each price covers. Another 18 list it but are not ranked, each with the reason on this page.

We also found 11 sellers offering BPC-157 with no real prescription check, often as "research use only". We do not rank them or name them here.

Legal checks carry the most weight in our scores. We look for a state license, a prescription before checkout, single-ingredient products, routes the policy covers, and any FDA warning letters. Quality checks include a named, FDA-registered ingredient maker and batch certificates of analysis. We also check whether prices and the states served are public.

Prices and fees change often. Check them, and the states served, on the provider's own page before you book a visit. The research for this page was done on October 29, 2026.